Satya Das

Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Manisha H. Shah, Whitney Goldner, Al B. Benson et al. · Journal of the National Comprehensive Cancer Network · 2021 · 542 citations

Surgical Oncology, Adrenal Tumors, Pathology +19

Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti–PD-1/PD-L1 therapy

Jordan Roberts, Raul S. González, Satya Das et al. · Human Pathology · 2017 · 51 citations · Full text

Gastrointestinal Oncology, Medicine, Anti–pd-1/pd-l1 Therapy +7

Improving the phenotype risk score as a scalable approach to identifying patients with Mendelian disease

Lisa Bastarache, Jacob Hughey, Jeffrey A. Goldstein et al. · Journal of the American Medical Informatics Association · 2019 · 50 citations · Full text

Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer

İbrahim Halil Şahin, Subir Goyal, Yoanna S Pumpalova et al. · The Oncologist · 2021 · 46 citations · Full text

Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy

Satya Das, Kristen K. Ciombor, Sigurdís Haraldsdóttir et al. · The Oncologist · 2020 · 42 citations · Full text

Irae Onset, Cancer Management, Immunology +24